PRIA Logo™
114-hr-5573114th Congress

PRICED Act

Sponsored By: Representative Schakowsky, Janice D. [D-IL-9]

Unknown

Summary

Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act This bill amends the Public Health Service Act to allow biosimilars to be marketed seven years after the reference brand name biological product is licensed. Currently, brand name biological products are provided a 12-year marketing exclusivity period. This shortened marketing exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

No Economic Impacts Identified for this Bill

Sponsors & CoSponsors

Sponsor

Schakowsky, Janice D. [D-IL-9]

IL • D

Cosponsors

  • ELIJAH CUMMINGS

    MD • D

    Sponsored 6/23/2016

  • JIM MCDERMOTT

    WA • D

    Sponsored 6/23/2016

  • Rep. Doggett, Lloyd [D-TX-37]

    TX • D

    Sponsored 6/23/2016

  • Sen. Welch, Peter [D-VT]

    VT • D

    Sponsored 6/23/2016

  • Rep. Kaptur, Marcy [D-OH-9]

    OH • D

    Sponsored 6/24/2016

  • Rep. DeLauro, Rosa L. [D-CT-3]

    CT • D

    Sponsored 6/24/2016

  • Rep. Kirkpatrick, Ann [D-AZ-1]

    AZ • D

    Sponsored 7/13/2016

  • Rep. Walz, Timothy J. [D-MN-1]

    MN • D

    Sponsored 9/28/2016

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation